SNSE

Sensei Biotherapeutics, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Fundamentals are temporarily unavailable for SNSE.

SNSE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$30.38M	$18.30M	$18.63M	$10.96M
Selling, General & Admin	$19.80M	$18.77M	$13.04M	$11.33M
Operating Expenses	$50.19M	$37.06M	$31.66M	$22.29M
Operating Income	-$50.19M	-$37.06M	-$31.66M	-$22.29M
EBITDA	-$47.02M	-$32.61M	-$28.75M	-$20.91M
Pretax Income	-$48.59M	-$34.10M	-$30.16M	-$21.09M
Net Income	-$48.59M	-$34.10M	-$30.16M	-$21.09M
Diluted EPS	-31.60	-24.40	-24.00	-16.72
Diluted Shares	1.54M	1.40M	1.26M	1.26M

SNSE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$17.80M	$13.01M	$9.99M	$8.67M
Current Assets	$108.59M	$67.25M	$41.93M	$21.51M
Total Assets	$118.38M	$74.37M	$45.36M	$22.90M
Current Liabilities	$9.07M	$5.64M	$5.45M	$4.25M
Total Debt	$8.03M	$6.21M	$3.85M	$1.51M
Total Liabilities	$14.97M	$9.48M	$6.97M	$4.31M
Retained Earnings	-$197.79M	-$231.90M	-$262.05M	-$283.14M
Shareholders' Equity	$103.41M	$64.89M	$38.39M	$18.59M
Working Capital	$99.52M	$61.61M	$36.48M	$17.26M

SNSE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$39.03M	-$32.02M	-$24.67M	-$20.45M
Capital Expenditure	-$321.00K	-$180.00K	-$146.00K	-$16.00K
Free Cash Flow	-$39.35M	-$32.20M	-$24.82M	-$20.47M
Depreciation & Amortisation	$1.35M	$1.35M	$1.32M	$139.00K
Stock-Based Compensation	$5.81M	$4.45M	$3.13M	$1.27M
Investing Cash Flow	$49.95M	$38.41M	$22.44M	$19.77M
Financing Cash Flow	-$287.00K	-$11.17M	-$787.00K	-$645.00K
Share Repurchases	$0.00	-$10.38M	$0.00	-$1.00K
Net Change in Cash	$10.64M	-$4.78M	-$3.02M	-$1.33M

SNSE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.73M	$2.53M	$2.54M	$2.17M	$150.91M
Selling, General & Admin	$3.55M	$2.67M	$2.31M	$2.79M	$19.71M
Operating Expenses	$7.27M	$5.21M	$4.85M	$4.96M	$170.63M
Operating Income	-$7.27M	-$5.21M	-$4.85M	-$4.96M	-$170.63M
EBITDA	-$7.24M	-$4.89M	-$4.53M	-$4.68M	-$170.60M
Pretax Income	-$6.86M	-$4.94M	-$4.57M	-$4.72M	-$170.24M
Net Income	-$6.86M	-$4.94M	-$4.57M	-$4.72M	-$170.24M
Diluted EPS	-5.40	-3.91	-3.62	—	-131.45
Diluted Shares	1.26M	1.26M	1.26M	—	1.30M

SNSE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$9.88M	$12.56M	$10.56M	$8.67M	$152.32M
Current Assets	$35.68M	$29.57M	$25.79M	$21.51M	$204.23M
Total Assets	$38.27M	$31.78M	$27.59M	$22.90M	$205.38M
Current Liabilities	$5.23M	$3.87M	$4.44M	$4.25M	$14.19M
Total Debt	$3.21M	$2.56M	$2.02M	$1.51M	$1.04M
Total Liabilities	$6.29M	$4.47M	$4.58M	$4.31M	$342.67M
Retained Earnings	-$268.92M	-$273.85M	-$278.42M	-$283.14M	-$453.37M
Shareholders' Equity	$31.99M	$27.31M	$23.01M	$18.59M	-$137.29M
Working Capital	$30.45M	$25.70M	$21.35M	$17.26M	$190.04M

SNSE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$7.09M	-$5.91M	-$3.59M	-$3.86M	-$10.73M
Capital Expenditure	—	—	—	—	-$6.00K
Free Cash Flow	-$7.09M	-$5.92M	-$3.59M	-$3.86M	-$10.74M
Depreciation & Amortisation	$34.00K	$37.00K	$34.00K	$34.00K	$30.00K
Stock-Based Compensation	$461.00K	$264.00K	$254.00K	$295.00K	$12.90M
Investing Cash Flow	$7.19M	$8.76M	$1.74M	$2.08M	-$31.44M
Financing Cash Flow	-$214.00K	-$168.00K	-$152.00K	-$111.00K	$185.83M
Share Repurchases	$0.00	-$1.00K	$0.00	$0.00	-$15.14M
Net Change in Cash	-$117.00K	$2.68M	-$2.00M	-$1.89M	$143.66M

Market Snapshot

About

Sensei Biotherapeutics is a clinical-stage immunotherapy company developing next-generation therapeutics for cancer treatment. The company focuses on innate immunity to develop conditionally-activated immunotherapies designed to overcome tumor resistance mechanisms. Sensei is advancing multiple programs targeting both solid tumors and hematologic malignancies.